SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/A01F5067F6F513E90D48A26C981E3D820FF212A295CDF6C3B2ABEF3BC2ADD7AA509DCDAA747FE796B411DCF381C84DA2>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/A01F5067F6F513E90D48A26C981E3D820FF212A295CDF6C3B2ABEF3BC2ADD7AA509DCDAA747FE796B411DCF381C84DA2
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/A01F5067F6F513E90D48A26C981E3D820FF212A295CDF6C3B2ABEF3BC2ADD7AA509DCDAA747FE796B411DCF381C84DA2
http://www.w3.org/2000/01/rdf-schema#comment
"Data suggest simultaneous silencing of vascular endothelial growth factor (VEGF) and Survivin using the dual siRNA may be an advantageous alternative for the development of therapeutic strategies against human osteosarcoma."
xsd:string
http://purl.uniprot.org/uniprot/#_DCECABC72CEEEDAECB16691D18687A7E8C755B362B978F6A8E0561AB4C0CD1C7D74D44D5F08420F86018BA033CEF809D
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/A01F5067F6F513E90D48A26C981E3D820FF212A295CDF6C3B2ABEF3BC2ADD7AA509DCDAA747FE796B411DCF381C84DA2
http://purl.uniprot.org/uniprot/G3FM75
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/A01F5067F6F513E90D48A26C981E3D820FF212A295CDF6C3B2ABEF3BC2ADD7AA509DCDAA747FE796B411DCF381C84DA2
http://purl.uniprot.org/uniprot/#_G3FM75-mappedCitation-30566604
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/A01F5067F6F513E90D48A26C981E3D820FF212A295CDF6C3B2ABEF3BC2ADD7AA509DCDAA747FE796B411DCF381C84DA2